Pegfilgrastim biosimilar - Gedeon Richter

Drug Profile

Pegfilgrastim biosimilar - Gedeon Richter

Alternative Names: Cavoley - STADA Arzneimittel; Efgratin - Gedeon Richter; Pegylated human granulocyte colony stimulating factor - Gedeon Richter; RGB-02

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Gedeon Richter
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Submission Withdrawal Neutropenia

Most Recent Events

  • 04 Oct 2017 Gedeon Richter completes a phase I trial in Healthy volunteers in United Kingdom (SC) (NCT03146988)
  • 08 Sep 2017 Efficacy and adverse events data from a phase III trial in Neutropenia presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 10 Apr 2017 Gedeon Richter initiates enrolment in a phase I trial in Healthy individuals in United Kingdom (NCT03146988)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top